Precision dosing for resistant infections in intensive care
Treatments studied
Part of Infections clinical trials.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You are currently in the intensive care unit (ICU) with a severe infection.
- You have not taken ceftazidime-avibactam in the 15 days before joining.
- Your infection is caused by bacteria that are resistant to carbapenem antibiotics (a group of strong antibiotics), confirmed by a lab test.
- You will receive ceftazidime-avibactam for more than 72 hours as part of your treatment.
- You are able to provide samples (like sputum, blood, or fluid from your abdomen) for testing before starting the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This study tests two ways of giving the antibiotic ceftazidime/avibactam (as a continuous drip or as intermittent shots) to patients in the intensive care unit with severe infections. The goal is to see which method works better or is safer for critically ill patients.
This trial tests a specific antibiotic combination (ceftazidime-avibactam) in patients with serious infections that are resistant to other antibiotics, while they are in intensive care. The goal is to see how well this treatment works for critically ill patients.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Hear when a new ECMO trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.